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Background: Depression and coronary heart disease (CHD) are frequently comorbid and portend higher morbidity,
mortality and poorer quality of life. Prior systematic reviews of depression treatment randomized controlled trials
(RCTs) in the population with CHD have not assessed the efficacy of collaborative care. This systematic review aims
to bring together the contemporary research on the effectiveness of collaborative care interventions for depression
in comorbid CHD populations.
Methods/Design: Electronic databases (Cochrane Central Register of Controlled Trials MEDLINE, EMBASE, PsycINFO
and CINAHL) will be searched using a sensitive search strategy exploding the topics CHD, depression and RCT. Full
text inspection and bibliography searching will be conducted, and authors of included studies will be contacted to
identify unpublished studies. Eligibility criteria are: population, depression comorbid with CHD; intervention, RCT of
collaborative care defined as a coordinated model of care involving multidisciplinary health care providers, including:
(a) primary physician and at least one other health professional (e.g. nurse, psychiatrist, psychologist), (b) a structured
patient management plan that delivers either pharmacological or non-pharmacological intervention, (c) scheduled
patient follow-up and (d) enhanced inter-professional communication between the multiprofessional team;
comparison, either usual care, enhanced usual care, wait-list control group or no further treatment; and outcome, major
adverse cardiac events (MACE), standardized measure of depression, anxiety, quality of life, cost-effectiveness. Screening,
data extraction and risk of bias assessment will be undertaken by two reviewers with disagreements resolved through
discussion. Meta-analytic methods will be used to synthesize the data collected relating to the outcomes.
Discussion: This review will evaluate the effectiveness and cost-effectiveness of collaborative care for depression in
populations primarily with CHD. The results will facilitate integration of evidence-based practice for this precarious
population.
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The prevalence of depression disorder is estimated at
between 15%–20% in the coronary heart disease (CHD)
population, while clinically relevant depressive symp-
toms are prevalent in up to 40% of this group [1-3].
Moreover, depression is widely documented to lead to
an adverse CHD prognosis [4-8]. Specifically, depression
disorder and depressive symptoms have been linked to a
twofold higher risk of death [4] and a higher risk for
subsequent major adverse cardiac events (MACE) in-
cluding myocardial infarction or coronary revasculariza-
tion [9]. Also, depression is associated with diminished
quality of life [6,7,10] and failure to make gains in qua-
lity of life after coronary revascularization in longitudinal
studies [11]. Considering that depression is a modifiable
risk factor yet portends subsequent MACE risk, it has
been hypothesized that depression intervention in the
CHD population could lead to fortuitous benefits to an
otherwise poorer CHD prognosis [12,13].
Unfortunately, prior psychological and pharmacolo-
gical depression intervention efforts in the CHD popula-
tion have reported only small, albeit significant, effects
on depression symptoms [14]. Moreover, and conspicu-
ously, previous trials including the landmark ENRICHD
study [13] have not led to a significant reduction in
MACE [14], raising questions about the design [15] and
acceptability [16] of depression interventions in the
population with CHD, especially in the period after an
acute myocardial infarction. More recently, collaborative
care has emerged as a potentially promising model of
health care among populations with complex mental
health needs [17] and also mental health needs comorbid
with chronic diseases such as diabetes [18] and CHD
[19]. Collaborative care is defined by a multi-professional
approach to patient care delivered by a physician and at
least one other health professional, involving a structured
patient management plan and interventions, scheduled
patient follow-ups and enhanced inter-professional com-
munication between the multi-professional team [19].
In a 2012 review of collaborative care for depression in
medically ill patients, it was noted that evidence was, at
that time, sparse in relation to the efficacy of collabora-
tive care and chronic disease-specific outcomes [20].
Moreover, the authors noted that there was no evidence
for the cost-effectiveness of collaborative care in the
population with chronic diseases [20], calling into ques-
tion the applicability of this particular model of care to
health care policy makers and clinicians. Subsequently,
Huang and colleagues [18] reported a systematic review
and meta-analysis of eight randomized controlled trials
(RCTs) regarding collaborative care for depression comor-
bid with diabetes. The review revealed that collaborative
care was associated with depression remission (risk ratio
(RR) = 1.53, 95% confidence interval [CI] =1.11–2.12)indicating that evidence relating to the efficacy of collab-
orative care for chronic disease-specific populations is
emerging [18].
However, the collaborative care evidence basis in the
population with CHD has not been subject to systematic
review and meta-analysis. Indeed, prior reviews [21-23]
have evaluated a single RCT comprised of CHD patients
[24], although mixed CHD and diabetes samples were in-
cluded [19], whereas other collaborative care depression
interventions in the CHD population [25] was included in
only one review [23]. Further to such limitations to date,
several large prospective RCTs of collaborative depression
care have been reported in CHD populations [26-28] rais-
ing the possibility to evaluate the efficacy and early bene-
fits of collaborative care. A systematic review of this type,
as described herein in protocol stage, might in turn assist
in the design of subsequent trials and inform clinicians.
Moreover, an evaluation of the extant literature’s study
quality and cost-effectiveness might inform clinical prac-
tice and assist health care policy makers’ integration of the
results into models of care. Herein, we outline a sys-
tematic review and meta-analysis protocol designed to
overcome the abovementioned limitations pertaining to




The proposed review aims to synthesize the evidence
base of RCTs reporting the effectiveness of collaborative
depression care in persons with CHD with respect to
MACE risk, depression, anxiety, quality of life and cost-
effectiveness. The reporting of this review will conform
to the PRISMA guidelines [29].
Eligibility criteria
 Population: studies must be performed among adults
(18 years and older) with comorbid depression and
CHD. Depression must be defined as depression
disorder or clinical depression assessed according to
the Diagnostic and Statistical Manual of Mental
Disorders (DSM) or International Classification of
Diseases (ICD) by a standardized interview (e.g.
Structured Clinical Interview, Composite
International Diagnostic Interview). However, in favor
of providing a more comprehensive overview, we will
also include trials using validated self-reports or rating
scales with specific cut-off points for depression.
Mixed samples (e.g. heart failure, arrhythmia,
diabetes) are eligible if ≥50% of the sample have a
CHD diagnosis, as the first large collaborative care
RCT for comorbid depression and chronic illness
included persons with CHD or diabetes [19].
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with collaborative care defined as a coordinated
model of care involving multidisciplinary health care
providers, including: (a) primary physician and at
least one other health professional (e.g. nurse,
psychiatrist, psychologist); (b) a structured patient
management plan that delivers either
pharmacological or non-pharmacological
intervention; (c) scheduled patient follow-up and
(d) enhanced inter-professional communication
between the multiprofessional team. Collaborative
care may include usual CHD care or blended
depression-CHD care.
 Comparison: a control group being either
(enhanced) usual care, wait-list control group, or no
further treatment for comorbid depression-CHD.
 Outcomes: primary, the primary outcome is
all-cause and CHD-related mortality as well as
non-fatal MACE (e.g. subsequent myocardial
infarction, revascularization procedure, incident
heart failure, stroke) and secondary, the secondary
outcomes include the effects of collaborative care on
depression (measured either dimensionally or
categorically) following the intervention assessed by
validated self-report questionnaires or standardized
interview. Other secondary outcomes include
anxiety and quality of life. Moreover, we will assess
economic evaluations of health care costs or
resource utilization and quality of life in
collaborative care. Specifically, this includes cost
cost-effectiveness (incremental cost-effectiveness
ratio) and cost-utility (quality-adjusted life years).
Study type
Only RCTs that are peer-reviewed studies in full text,
conference abstract or doctoral dissertations are eligible
for this review. Studies must be published in English or
German to be eligible. We will exclude cross-sectional
studies, case series and case reports.
Search strategy
We will identify relevant articles in any language by
searching electronic databases from inception including:
the Cochrane Central Register of Controlled Trials
(CENTRAL) on The Cochrane Library, MEDLINE,
EMBASE, PsycINFO and CINAHL. A highly sensitive
RCT filter will be used with the MEDLINE search, as pre-
viously reported by Higgins [30]. Importantly, as not all
interventions may identify as collaborative care (e.g. [27]),
we will utilize a comprehensive and broad search used
previously [14] encompassing the topics CHD, depression
and RCT without being limited to specific interventions.
The search strategy is provided in Additional file 1. We
will hand search the reference lists of articles selected forfull text to supplement the electronic searches. The princi-
pal investigators of studies will be contacted to clarify
study eligibility if required. Primary authors will also be
contacted to ascertain missing or unpublished data and
their knowledge of any other collaborative care trials not
retrieved by our primary search.
Study selection process
Initially, two reviewers (PJT, HB) will independently
screen titles and abstracts of all the retrieved bib-
liographic records. Full texts of all potentially eligible
records passing the title and abstract screening level will
be retrieved and examined independently by two re-
viewers with the abovementioned eligibility criteria [29].
Disagreements at both screening levels (title/abstract
and full text) will be resolved through discussion or
adjudication of a third reviewer. A PRISMA flow chart
will outline the study selection process and reasons for
exclusions.
Data items for collection
After determination of the initial study, eligibility informa-
tion will be extracted for each study pertaining to study
identification (first author, year of publication, country
where recruitment took place), study design charac-
teristics (sample size, intervention design, duration of
intervention, % receiving antidepressants, % receiving psy-
chotherapy, number of intervention phone calls, length of
follow-up) and patient population (age, gender, % CHD).
Primary outcome data collected at the conclusion of the
intervention will include MACE. Secondary outcome
data will include depression severity, response and re-
mission (measured either dimensionally or catego-
rically), health-related quality of life, anxiety symptoms
and cost-effectiveness. These variables will be extracted
for all studies, after which the extracted data will be
verified by a second reviewer to reduce reviewer errors
and bias. All disagreements will be handled by consen-
sus from the three adjudicators.
There is a likelihood of more than one reported eligible
outcome per study [31], we will include data as follows:
1. in the case of available data from both rating scales (e.g.
Hamilton Rating Scale for Depression) and self-report
questionnaires (e.g. Beck Depression Inventory), data from
rating scales will be prioritized and 2. in the case where
several outcome measures of the same hierarchy level are
used in one study, we will select the outcome measure
that is used most frequently across the eligible studies.
Risk of bias
Two reviewers will independently assess the risk of bias
in duplicate of the included studies using the Cochrane
Collaboration’s tool for assessing risk of bias in RCTs
[30]. With regard to psychological interventions,
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the treatment is not feasible, but an evaluation of out-
comes can be performed by researchers that are un-
aware of the treatment allocation of patients. Trials of
psychological interventions will therefore be evaluated
regarding the blinding of the outcome assessors. In
pharmacological trials, blinding is possible for patients,
personnel and outcome assessor and will be evaluated
accordingly. The impact of possible bias in altering the
results will then be evaluated, and conclusions concer-
ning an overall risk of bias for primary and secondary
outcomes will be drawn. For each included RCT, we will
provide a description, comment and judgment of risk as
‘Low’ , ‘Unclear’ or ‘High’ , for each of the items: random
sequence generation, allocation concealment, blinding
of participants and personnel (subjective and objective
outcomes), incomplete outcome data, selective report-
ing and other bias (see Table 1).
Synthesis of data and summary measures
Data synthesis and meta-analysis
For all included RCTs, we will provide a detailed de-
scription of the results in both tables and text. We will
use RevMan 5.2 to conduct the meta-analyses. When
data is available to be pooled together, we will use a
random-effects model using the inverse-variance me-
thod outlined by DerSimonian and Laird which is a
more conservative estimate of effect size [32]. Where
possible, we will aggregate each included RCT’s MACE
data for the intervention and control group as di-
chotomous variables with the RR and 95% CI. When
studies report depression and/or anxiety remission among
the intervention and control group as a dichotomousTable 1 Outline of risk of bias assessment
Aspect of trial bias
assessed





2. Allocation concealment Selection bias
3. Blinding of participants and
personnel
Performance bias
4a. Blinding of outcome
assessment - subjective
outcomes
Detection bias; e.g. depression
symptoms measured on a standardized
self-report questionnaire
4b. Blinding of outcome
assessment - objective
outcomes
Detection bias; e.g. depression
remission measured by a structured
clinical interview
5. Incomplete outcome data Attrition bias
6. Selective reporting Reporting bias
7. Other bias e.g. when bias may seriously alter the
results, such as improper adjustment
for baseline imbalances or funding biasoutcome, we will also aggregate this data with the RR and
95% CI. Health care costs reported as incremental cost-
effectiveness ratio will be aggregated with the RR and 95%
CI. Otherwise, continuous outcome data (e.g. depression
symptoms, anxiety symptoms, quality of life, total costs)
between the intervention and control group will be ana-
lyzed with the SMD. The SMD is calculated as the dif-
ference between the intervention and control means in
each trial divided by the estimated between-person stan-
dard deviation (SD) for that trial.
Due to the nature of outcomes assessed in the review,
it is possible that studies will report multiple observa-
tions with heterogeneity concerning the follow-up
length of the outcome assessment [14,31]. We will ana-
lyse follow-up durations using different time frames: 1.
short term (up to 6 months post-treatment); 2. medium
term (6–12 months post-treatment) and 3. long term
(more than 12 months post-treatment). Our inclusion
criteria do not specify requisite time points at which
outcomes are measured to avoid excluding potentially
useful information; however, we will account for timing
during data analysis. We intend to group all studies to-
gether initially and then perform sensitivity analyses for
different time points (e.g. depression in the short,
medium and long term), if possible.
It is possible that individual studies may consist of
multiple treatment groups, such as different types of
depression interventions or different doses of medica-
tion. In order to avoid the possibility of introducing bias
caused by multiple statistical comparisons with one
control group, we will combine the groups from
multiple-arm studies into a single group.Assessment of heterogeneity
Heterogeneity will be evaluated with the I2 statistic.
According to the Cochrane Handbook for Systematic
Reviews of Interventions [30], I2 of 0%–60% can be
regarded as not important to moderate (0%–60%), while
I2 > 60% indicates substantial heterogeneity. The results
of this assessment will guide the decision whether to
perform meta-analyses or not and whether to base the
analyses on a random-effects or a fixed-effect model.
We have considered the following to explain poten-
tial sources of heterogeneity between the included
RCT studies: (1) trials with a higher risk of bias will
show larger effects than trials with lower risk of bias
[30] and (2) trials comprised by a proportion of pa-
tients with diabetes will contain larger effect sizes
than trials consisting of CHD patients only [14,33].Assessment of publication bias
The presence of publication bias will be evaluated
using the test of Egger et al. [34] and the funnel plot.
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Sensitivity analyses will assess sub-groups restricted to
(1) studies consisting of only CHD patients and not in-
clusive of mixed chronic diseases such as diabetes, (2)
studies utilizing a standardized psychiatric interview and
(3) studies with a low overall risk of bias.GRADE framework
The proposed review will use the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) guidelines [35] to determine the quality and
strength of recommendations.Discussion
This systematic review may add to the extant literature
by reporting the efficacy of collaborative care depression
interventions in CHD populations with respect to
MACE, depression, anxiety, quality of life and health
care costs. It is feasible that the findings of our review
will extend beyond previous systematic reviews inclu-
ding a Cochrane review in the coronary artery disease
population [14]. As such, the proposed systematic review
will be interpreted alongside prior high-quality syste-
matic reviews of depression treatment in CHD [14] and
those prior systematic reviews pertaining to collaborative
depression care in diabetes [18] and chronic illnesses
[22,23]. The findings might therefore serve to inform the
design of future RCTs, evidence-based clinical practice
and health care policy, especially relating to the effec-
tiveness and cost-effectiveness of collaborative depres-
sion care in CHD.
There are several limitations that will contextualize
the findings and generalizability of the proposed review
including the relative infancy of the collaborative care
literature in the CHD population with depressive symp-
toms. Limitations of the original studies may also in-
clude between-study heterogeneity and high risk of bias
that will potentially limit the conclusions drawn. Spe-
cifically, although blinding of treatment allocation is not
feasible in depression RCTs, it is possible that systematic
bias may relate to assessment of depressive symptoms by
non-blinded study assessors. Moreover, trials may utilize
different depression measures, incorporating different
symptoms with discrepant validity in the population
with CHD. Therefore, the proposed review may be
limited by the pooling together of depression and other
patient-reported outcome measures with divergent psy-
chometric properties. Finally, despite attempts to retrieve
unpublished and non-significant studies, the proposed
systematic review is likely to be limited by publication bias
of only significant findings, given the infancy of the litera-
ture [36]. Finally, as the proposed review will include only
English and German language studies, the generalizabilityof the findings from studies published in other languages
and other health care settings is limited.
In conclusion, given the emergence of collaborative
care depression intervention evidence in chronic disease
populations including CHD, and the absence of a sys-
tematic review, this review will help in summarizing the
available evidence, both quantitatively and qualitatively.
Additional file
Additional file 1: Search strategy.
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